Table 1_Muscle quality index and hyperuricemia: adipose tissue as a mediator.docx by Ya Shao (16975896)

“…Each one-unit increment in MQI corresponded to a 50% decrease in the odds of hyperuricemia (OR: 0.50, 95% CI: 0.43–0.57). …”

Table_2_A Population of M2 Macrophages Associated With Bone Formation.docx by Elizabeth Olmsted-Davis (11552029)

Rates of Gyrase Supercoiling and Transcription Elongation Control Supercoil Density in a Bacterial Chromosome by Nikolay Rovinskiy (144279)

Table_1_A Population of M2 Macrophages Associated With Bone Formation.docx by Elizabeth Olmsted-Davis (11552029)

Data_Sheet_3_Analysis of COVID-19-Related RT-qPCR Test Results in Hungary: Epidemiology, Diagnostics, and Clinical Outcome.PDF by Katalin Gombos (10033505)

Data_Sheet_2_Analysis of COVID-19-Related RT-qPCR Test Results in Hungary: Epidemiology, Diagnostics, and Clinical Outcome.PDF by Katalin Gombos (10033505)

Data_Sheet_1_Analysis of COVID-19-Related RT-qPCR Test Results in Hungary: Epidemiology, Diagnostics, and Clinical Outcome.PDF by Katalin Gombos (10033505)

Data_Sheet_4_Analysis of COVID-19-Related RT-qPCR Test Results in Hungary: Epidemiology, Diagnostics, and Clinical Outcome.PDF by Katalin Gombos (10033505)

Image_8_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif by Carolina do Prado Servian (17115112)

“…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”

Image_7_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif by Carolina do Prado Servian (17115112)

“…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”

Image_10_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif by Carolina do Prado Servian (17115112)

“…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”

Image_15_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif by Carolina do Prado Servian (17115112)

“…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”

Image_13_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif by Carolina do Prado Servian (17115112)

“…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”

Image_11_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif by Carolina do Prado Servian (17115112)

“…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”

Image_14_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif by Carolina do Prado Servian (17115112)

“…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”

Image_6_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif by Carolina do Prado Servian (17115112)

“…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”

Image_1_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif by Carolina do Prado Servian (17115112)

“…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”

Image_4_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif by Carolina do Prado Servian (17115112)

“…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”

Image_12_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif by Carolina do Prado Servian (17115112)

“…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”

Image_2_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif by Carolina do Prado Servian (17115112)

“…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”